UNSPSC 51191520: Polythiazide

This classification denotes a thiazide diuretic with the molecular formula C11H13ClF3N3O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36780APV5N, chemically known as 6-chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2h-benzo-1,2,4-thiadiazine 1,1-dioxide but generally known as polythiazide, which bears US NIH Compound Identifier 4870. European Medicines Agency schedules Polythiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09976MIG.

UNSPSC 51191520 Polythiazide is a Commodity code that in practice captures municipal procurement of water-treatment chemicals and pharmaceutical products for state and local health and facility operations. Recent solicitations show the code tagged to sodium bisulfite for municipal water pollution control and to generic multi-source pharmaceuticals and over-the-counter products for state and local government health facilities, indicating a broad scope spanning industrial water-treatment inputs and pharmaceutical supply. State and local buyers under this code include municipalities (city public works and water authorities), state departments of administration overseeing cooperative purchasing alliances, and participating health facilities across multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat issuer in pharmaceutical procurement under cooperative purchasing vehicles that serve multiple states including Oregon.

Geographic activity concentrates in the Upper Midwest and Northeast, with documented recent solicitations from Connecticut (City of Meriden) and Minnesota (MMCAP). Representative recent opportunities include the City of Meriden's IFB B027-15 for sodium bisulfite chemical supply to its Water Pollution Control Facility, due July 29, 2026, requiring General Liability and Auto Liability coverage with Connecticut-approved carriers and performance and payment bonds; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026, requiring vendor participation through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. as authorized wholesalers, compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and a 3 percent administrative fee on all contract purchases.